Answers are grounded in this paper and cite their sources.
To the Editor: Liver steatosis is frequent in HIV-infected patients as a result of several risk factors. Most studies analyze the incidence of cirrhosis in HIV-infected patients who are coinfected with hepatitis C virus (HCV). McGovern and colleagues1 published an article recently on the association between hepatic steatosis and fibrosis in patients coinfected with HIV and HCV. The authors observed a strong association between steatosis and the use of nucleoside analogues (especially didanosine and stavudine) and HCV genotype 3. Steatosis may also progress to fibrosis. This retrospective study included 183 patients who had had a liver biopsy a few years previously. Steatosis was present in approximately two thirds of patients and was associated with fibrosis (odds ratio [OR] = 1.37; 95% confidence interval [CI]: 1.03 to 1.81; P = 0.029). The influence of steatosis on fibrosis is poorly understood, however. We have observed 2 cases of rapid progression of disseminated macrovacuolar steatofibrosis to cirrhosis in patients free of HCV infection. Neither patient had a history of alcohol abuse or intravenous drug use, and both tested negative for HCV (serology and polymerase chain reaction [PCR] RNA) and hepatitis B surface (HBs) antigen. The first patient had a history of hypertriglyceridemia, but it had been controlled with dietary measures for 4 years before biopsy. The first liver biopsy showed disseminated macrovacuolar steatosis (>80%). The patient then developed cytolysis and had an uncontrolled HIV viral load. The second biopsy was performed 2 years later, when HIV infection was controlled by highly active antiretroviral therapy (HAART). It showed regression of steatosis (10%) and progression of fibrosis with signs of cirrhosis. The second patient had a long history of HIV infection. He also had uncontrolled dyslipidemia. The first biopsy was done during a period of uncontrolled HIV infection and elevated liver enzyme activities. It showed major macrovacuolar steatosis (>80%). The second biopsy was done 6 years later and showed the same degree of steatosis and also signs of cirrhosis. HIV infection was under control at that time. The prevalence of steatosis in HIV-infected patients without classic risk factors is not known, whereas it is well documented in HCV/HIV-coinfected patients, as is the progression from steatosis to fibrosis.2 Some patients may progress quickly to cirrhosis, as our second patient did. This raises monitoring issues, because liver biopsy is the only validated way of evaluating steatosis in HIV-infected patients. The cases reported here show that liver steatosis can progress rapidly to cirrhosis in HIV-infected/HCV-negative patients, despite effective control of HIV infection. A role of HAART seems likely, given the observed lipodystrophy, insulin resistance, and hypertriglyceridemia.3 Thus, liver steatosis can rapidly progress to cirrhosis in patients with no potential risk factors but HAART. Pierre Loulergue, MD, MSc* Patrice Callard, MD, PhD† Philippe Bonnard, MD* Gilles Pialoux, MD, PhD* *Service des Maladies Infectieuses Hôpital Tenon Université Paris VI Paris, France †Service d'Anatomopathologie Hôpital Tenon Université Paris VI Paris, France
No takes yet. Share an insight, caveat, or question.
Loulergue et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: